This database contains 5 studies, archived under the term: "Ireland"
Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients–an open-label trial
Kennelly, Sean,
Abdullah, Laila,
Kenny, Rose Anne,
Mathura, Venkat,
Luis, Cheryl A.,
Mouzon, Benoit,
Crawford, Fiona,
Mullan, Michael,
Lawlor, Brian
Background: Evidence suggests that dihydropyridine calcium channel blockers may be useful in preventing and treating Alzheimer’s disease (AD).; Objective: In an open-label trial of safety and tolerability of nilvadipine in patients with AD, we examined cognition and executive function over a short time period to determine an influence of nilvadipine on these outcomes.; Method: We […]
Effectiveness of a structured education reminiscence-based programme for staff on the quality of life of residents with dementia in long-stay units: a study protocol for a cluster randomised trial
O'Shea, Eamon,
Devane, Declan,
Murphy, Kathy,
Cooney, Adeline,
Casey, Dympna,
Jordan, Fionnuala,
Hunter, Andrew,
Murphy, Edel
Background: Current projections indicate that there will be a significant increase in the number of people with dementia in Ireland, from approximately 40,000 at present to 100,000 by 2036. Psychosocial interventions, such as reminiscence, have the potential to improve the quality of life of people with dementia. However, while reminiscence is used widely in dementia […]
The impact of supplemental macular carotenoids in Alzheimer’s disease: A randomized clinical trial
Nolan, John M.,
Loskutova, Ekaterina,
Howard, Alan,
Mulcahy, Riona,
Moran, Rachel,
Stack, Jim,
Bolger, Maggie,
Coen, Robert F.,
Dennison, Jessica,
Akuffo, Kwadwo Owusu,
Owens, Niamh,
Power, Rebecca,
Thurnham, David,
Beatty, Stephen
Background: Patients with Alzheimer’s disease (AD) exhibit significantly less macular pigment (MP) and poorer vision when compared to control subjects. Objective: To investigate supplementation with the macular carotenoids on MP, vision, and cognitive function in patients with AD versus controls. Methods: A randomized, double-blind clinical trial with placebo and active arms. 31 AD patients and […]
A comparison of neuropsychiatric and cognitive profiles in delirium, dementia, comorbid delirium-dementia and cognitively intact controls
Meagher, D. J.,
Leonard, M.,
Donnelly, S.,
Conroy, M.,
Saunders, J.,
Trzepacz, P. T.
Purpose: Delirium and dementia have overlapping features that complicate differential diagnosis. Delirium symptoms overshadow dementia symptoms when they co-occur, but delirium phenomenology in comorbid cases has not been compared to both conditions alone.; Methods: Consecutive adults with DSM-IV delirium, dementia, comorbid delirium-dementia and cognitively intact controls were assessed using the Revised Delirium Rating Scale (DRS-R98) […]
Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study
Kennelly, S. P.,
Abdullah, L.,
Paris, D.,
Parish, J.,
Mathura, V.,
Mullan, M.,
Crawford, F.,
Lawlor, B. A.,
Kenny, R. A.
Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the […]